David A. Siegel 2seventy Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,600 shares of TSVT stock, worth $56,356. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,600
Previous 54,500
73.21%
Holding current value
$56,356
Previous $232,000
66.38%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TSVT
# of Institutions
127Shares Held
47.8MCall Options Held
84.3KPut Options Held
53.7K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$23 Million3.34% of portfolio
-
Morgan Stanley New York, NY4.36MShares$16.8 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$16.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.91MShares$15.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.73MShares$14.4 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $146M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...